Iterum Therapeutics Plc Stock Today
| ITRM Stock | USD 1.81 0.04 2.26% |
Performance9 of 100
| Odds Of DistressOver 69
|
Iterum Therapeutics is selling at 1.81 as of the 25th of November 2024; that is 2.26 percent increase since the beginning of the trading day. The stock's lowest day price was 1.69. Iterum Therapeutics has more than 69 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Iterum Therapeutics PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of May 2018 | Category Healthcare | Classification Health Care |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 27.52 M outstanding shares of which 2.53 M shares are currently shorted by private and institutional investors with about 0.46 trading days to cover. More on Iterum Therapeutics PLC
Moving against Iterum Stock
Iterum Stock Highlights
| CEO, Director | Corey Fishman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIterum Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Iterum Therapeutics' financial leverage. It provides some insight into what part of Iterum Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Iterum Therapeutics PLC (ITRM) is traded on NASDAQ Exchange in USA. It is located in Fitzwilliam Court, Dublin, Ireland, D02 YW24 and employs 14 people. Iterum Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 49.8 M. Iterum Therapeutics PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 27.52 M outstanding shares of which 2.53 M shares are currently shorted by private and institutional investors with about 0.46 trading days to cover.
Iterum Therapeutics PLC currently holds about 68.91 M in cash with (39.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Iterum Therapeutics Probability Of Bankruptcy
Ownership AllocationIterum Therapeutics PLC has a total of 27.52 Million outstanding shares. Roughly 89.21 (percent) of Iterum Therapeutics outstanding shares are held by general public with 1.81 % owned by insiders and only 8.98 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Iterum Ownership Details
Iterum Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Planning Capital Management Corp | 2024-09-30 | 40.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 12.0 | |
| Hm Payson & Co | 2024-09-30 | 3.0 | |
| Ubs Group Ag | 2024-06-30 | 1.0 | |
| Ancora Advisors Llc | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-06-30 | 0.0 | |
| Kelly Financial Services Llc | 2024-09-30 | 0.0 | |
| Millennium Management Llc | 2024-06-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 0.0 | |
| Armistice Capital, Llc | 2024-09-30 | 1.3 M | |
| New Leaf Venture Partners, L.l.c. | 2024-09-30 | 345 K |
Iterum Therapeutics Historical Income Statement
Iterum Stock Against Markets
Iterum Therapeutics Corporate Management
| Sailaja MD | Chief Officer | Profile | |
| Tom Loughman | Senior Operations | Profile | |
| Steven MD | Senior Development | Profile | |
| Louise Barrett | Senior Secretary | Profile | |
| Michael MD | Strategic Director | Profile | |
| Judith Matthews | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.